Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, November 10, 2022
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
[ Thu, Nov 10th 2022
] - WOPRAI
Drew Ranieri Maintained (BVS) at Buy with Decreased Target to $5 on, Nov 10th, 2022
Drew Ranieri of Morgan Stanley, Maintained "Bioventus Inc." (BVS) at Buy with Decreased Target from $11 to $5 on, Nov 10th, 2022.
Drew has made no other calls on BVS in the last 4 months.
There are 3 other peers that have a rating on BVS. Out of the 3 peers that are also analyzing BVS, 2 agree with Drew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Kyle Rose of "Canaccord Genuity" Downgraded from Strong Buy to Hold on, Wednesday, November 9th, 2022
- Amit Hazan of "Goldman Sachs" Maintained at Hold with Decreased Target to $13 on, Wednesday, September 7th, 2022
This is the rating of the analyst that currently disagrees with Drew
- Robbie Marcus of "JP Morgan" Downgraded from Buy to Sell on, Wednesday, November 9th, 2022
